Cargando…
Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review
In 2004, a chemical inhibitor of the kinase activity of EGFR was reported to be effective in a subset of lung cancer patients with activating somatic mutations of EGFR. It remained unclear, however, whether kinase fusion genes also play a major role in the pathogenesis of lung cancers. The discovery...
Autor principal: | Takeuchi, Kengo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433883/ https://www.ncbi.nlm.nih.gov/pubmed/30941048 http://dx.doi.org/10.3389/fphys.2019.00216 |
Ejemplares similares
-
GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential
por: Mulligan, Lois M.
Publicado: (2019) -
Cystic brain metastases and RET fusion in lung cancer
por: Remon, Jordi, et al.
Publicado: (2020) -
RET fusions observed in lung and colorectal cancers are sensitive to ponatinib
por: Gozgit, Joseph M., et al.
Publicado: (2018) -
Metabolomics of Head and Neck Cancer: A Mini-Review
por: Shin, Jae M., et al.
Publicado: (2016) -
Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
por: Guo, Robin, et al.
Publicado: (2019)